KCNQ2 and epilepsy: The severity of diseases such as KCNQ2-DEE, and the efficacy of the first-in-class neuronal Kv7 channel opener (retigabine; see below) in this and other seizure disorders have resulted in Kv7.2/3 being a major target for the development of novel anticonvulsants, but there have been difficulties in safe targeting of this channel, as described below.